Sphingosine-1-phosphate (S1P) activates STAT3 to protect against de novo acute heart failure (AHF)

Our data suggest that S1P protects in an ex-vivo rat heart model of AHF by activation of STAT3 and provide further evidence for the usage of S1P as a potential therapy in patients suffering from AHF.